The discovery of novel drivers of inflammation in psoriatic arthritis (PsA) have led to the identification of IL-17 which is produced by several cells, in addition to CD4+ T-helper (Th17) cells, and which raises the potential for novel pathogenic pathways in psoriasis and the PsA. This evidence concerns the gene IL17A and psoriasis.